Patents by Inventor Laurent P. Audoly

Laurent P. Audoly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES
    Publication number: 20100093611
    Abstract: Methods of treating, ameliorating, preventing, or reducing the risk of developing an auto-immune disease and/or an inflammatory condition, such as systemic lupus erythematosus, in a patient, such as a human being, using a therapeutically effective amount of an agent(s) that inhibits the activity of one or more of histone deacetylase (HDAC), IKB kinase (IKK-2), nuclear factor kB (NF-kB), ubiquitin/proteasome and Janus kinase (JAK) are disclosed. Compounds useful in such methods are also presented.
    Type: Application
    Filed: May 16, 2008
    Publication date: April 15, 2010
    Inventors: Stephen K. Horrigan, Qin Zong, Daniel Soppet, Juana Castaneda, Bo Chen, Ricardo Cibotti, Laurent P. Audoly, Anthony Coyle, Peter Kiener
  • Disruption of the glutathione S-transferase-Omega-1 gene
    Publication number: 20030131370
    Abstract: The invention features non-human mammals and animal cells that contain a targeted disruption of a glutathione S-transferase-Omega-1 gene. The invention also features methods of treating an IL-1 mediated and/or inflammation mediated disorder in a mammal comprising administering an agent that inhibits GST-Omega-1 activity.
    Type: Application
    Filed: November 18, 2002
    Publication date: July 10, 2003
    Applicant: Pfizer Inc.
    Inventors: Melanie R. Allen, Laurent P. Audoly, Christopher A. Gabel
  • Disruption of the prostaglandin E synthase 2 gene
    Publication number: 20030106085
    Abstract: The present invention features genetically-modified non-human mammals and animal cells containing a disrupted prostaglandin E synthase 2 gene as well as methods of treating an inflammation-mediated disorder involving administering an agent that inhibits prostaglandin E synthase 2.
    Type: Application
    Filed: November 13, 2002
    Publication date: June 5, 2003
    Applicant: Pfizer Inc.
    Inventors: Laurent P. Audoly, Omar L. Francone, Mehrdad Haghpassand, John E. Hambor, Marsha L. Roach, Jeffrey L. Stock